Ad-hoc | 25 February 2015 07:00
Fresenius SE & Co. KGaA / Key word(s): Final Results
25.02.2015 07:00
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Sales and net income at all-time highs - 6% Dividend increase proposed -
Positive Group outlook for 2015
Group sales increased by 14% (16% in constant currency) to EUR23,231
million (2013: EUR20,331 million). Organic sales growth was 4%. Currency
translation had a negative effect of 2%. Acquisitions contributed 12%.
Divestitures had a marginal effect on sales growth.
Group EBIT* increased by 4% (also 4% in constant currency) to EUR3,158
million (2013: EUR3,045 million). The EBIT margin was 13.6% (2013: 15.0%).
Group net income** increased by 3% (4% in constant currency) to EUR1,086
million (2013: EUR1,051 million). Earnings per share** increased by 3% (3%
in constant currency) to EUR2.01 (2013: EUR1.96, adjusted for 1:3 share
split in 2014).
Group net income (including special items) attributable to shareholders of
Fresenius SE & Co. KGaA increased by 6% (6% in constant currency) to
EUR 1,067 million (2013: EUR 1,011 million). Earnings per share increased
by 4% (5% in constant currency) to EUR 1.97 (2013: EUR 1.89, adjusted for
1:3 share split in 2014).
Based on the strong financial results, the Management Board will propose to
the Supervisory Board a dividend increase of 6% to EUR0.44 per share (2013:
EUR1.25 pre 1:3 share split).
For 2015, Fresenius projects sales growth of 7% to 10% in constant
currency. Net income*** is expected to increase by 9% to 12% in constant
currency.
The Group's U.S. GAAP financial results as of December 31, 2014 are
adjusted for special items. Adjusted earnings represent the Group's
business operations in the reporting period.
* Before special items: 2014 before integration costs (Fenwal EUR50 m;
acquired Rhön hospitals EUR51 m) and disposal gains (two HELIOS hospitals
EUR22 m; Rhön Stake EUR35 m); 2013 before integration costs
(Fenwal EUR54m)
** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
before special items: 2014 before integration costs (Fenwal EUR33 m;
acquired Rhön hospitals EUR41 m) and disposal gains (two HELIOS hospitals
EUR21 m; Rhön Stake EUR34 m); 2013 before integration costs
(Fenwal EUR40m)
*** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2015 before integration costs (~EUR10 million before tax for hospitals
acquired from Rhön-Klinikum AG), before costs for the efficiency program at
Fresenius Kabi (~EUR100 million before tax) and before the gain from the
divestment of two HELIOS hospitals (EUR34 million before tax); 2014 before
special items
(Financial statements according to U.S. GAAP)
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management
Bad Homburg v.d.H., February 25, 2015
End of note
25.02.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard),
Munich; Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Stuttgart; Terminbörse EUREX
End of Announcement DGAP News-Service
---------------------------------------------------------------------------